CIK 0001815442 · Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812992166
- Phone
- 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | Adams Brian Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +8,250 | 8,250 | ||
| 2026-03-02 | Chadwick Jeremy G Chief Operating Officer | Grant or award | +12,575 | 79,768 | ||
| 2026-03-02 | Chadwick Jeremy G Chief Operating Officer | Sale | −549 | $87.75 | $48K | 79,219 |
| 2026-03-02 | Chadwick Jeremy G Chief Operating Officer | Sale | −383 | $88.50 | $34K | 78,836 |
| 2026-03-02 | Chadwick Jeremy G Chief Operating Officer | Sale | −1,107 | $89.66 | $99K | 77,729 |
| 2026-03-02 | Chadwick Jeremy G Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +25,150 | 25,150 | ||
| 2026-03-02 | Goodman Noah Chief Business Officer | Grant or award | +9,225 | 59,306.44 | ||
| 2026-03-02 | Goodman Noah Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +18,450 | 18,450 | ||
| 2026-03-02 | Gollob Jared Chief Medical Officer | Grant or award | +17,650 | 127,642 | ||
| 2026-03-02 | Gollob Jared Chief Medical Officer | Sale | −1,510 | $87.75 | $133K | 126,132 |
| 2026-03-02 | Gollob Jared Chief Medical Officer | Sale | −1,055 | $88.50 | $93K | 125,077 |
| 2026-03-02 | Gollob Jared Chief Medical Officer | Sale | −3,048 | $89.66 | $273K | 122,029 |
| 2026-03-02 | Gollob Jared Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +35,300 | 35,300 | ||
| 2026-03-02 | Jacobs Bruce N. Chief Financial Officer | Grant or award | +17,650 | 245,059 | ||
| 2026-03-02 | Jacobs Bruce N. Chief Financial Officer | Sale | −2,039 | $87.75 | $179K | 243,020 |
| 2026-03-02 | Jacobs Bruce N. Chief Financial Officer | Sale | −1,424 | $88.50 | $126K | 241,596 |
| 2026-03-02 | Jacobs Bruce N. Chief Financial Officer | Sale | −4,113 | $89.66 | $369K | 237,483 |
| 2026-03-02 | Jacobs Bruce N. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +35,300 | 35,300 | ||
| 2026-03-02 | Mainolfi Nello Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +215,000 | 215,000 | ||
| 2026-02-25 | Mainolfi Nello Chief Executive Officer | Option exercise 10b5-1 | +30,000 | $2.08 | $62K | 696,195 |
Page 16 of 25 · 493 trades